


Attorney Docket No. 6567.200-US
 Sorensen et al.
 Serial No. 10/735,963
 Filed December 15, 2003

CLAIM LISTING

1. (Previously presented) A compound of the general formula (I):



wherein

R^1 is

C_{3-8} -cycloalkyl or C_{5-8} -cycloalkenyl,

- wherein the cyclic moieties may optionally be substituted with one or more substituents independently selected from R^{12} , wherein R^{12} is C_{1-6} -alkyl, halogen, trifluoromethyl or 2,2,2-trifluoroethyl,

r is 1,

s is 0, 1, 2 or 3,

t is 0, 1, 2 or 3,

X is $C=O$, $CHOH$ or CR^2R^3 ; wherein R^2 and R^3 independently are hydrogen or C_{1-6} -alkyl, or X is a bond,

Y is selected from the group consisting of oxadiazolyl, thiadiazolyl, or triazolyl, optionally substituted with one or more substituents independently selected from R^{18} ,

R^{18} is halogen, nitro, cyano, hydroxy, C_{1-6} -alkyl, C_{1-6} -alkylthio or C_{1-6} -alkoxy;

Attorney Docket No. 6567.200-US

Sorensen et al.

Serial No. 10/735,963

Filed December 15, 2003

R⁴ is

(a) C₁₋₆-alkyl, C₃₋₈-cycloalkyl or C₃₋₈-cycloalkenyl, which may optionally be substituted with one or more substituents independently selected from R¹³, wherein R¹³ is C₃₋₈-cycloalkyl, C₁₋₆-alkoxy, C₁₋₆-alkylthio, cyano, halo-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, and halogen,

or

(b) aryl, aryl-C₁₋₆-alkyl, aryl-C₂₋₆-alkenyl, or heteroaryl

which may optionally be substituted with one or more substituents independently selected from R¹⁴

R¹⁴ is

- halogen, nitro, cyano, acyl, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkylthio, C₁₋₆-alkylsulfonyl, C₁₋₆-alkylsulfonyloxy, C₁₋₆-alkoxy, C₃₋₈-cycloalkyl, halo-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, -NR⁵R⁶, R⁵R⁶N-C₁₋₆-alkyl-, R⁵R⁶N-C₁₋₆-alkoxy-, or -O(C=O)NR⁵R⁶, or wherein two substituents in adjacent positions together form a radical -O-(CH₂)₁₋₃-O-, wherein R⁵ and R⁶ independently are hydrogen, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₁₋₆-alkanoyl or aryl, or R⁵ and R⁶ together with the nitrogen atom to which they are attached form a 3 to 7 membered, saturated or unsaturated ring, which may be fused to a benzene ring,
- a group of the formula -(W)_k-A wherein

-(W)_k-A wherein

W is -C₁₋₆-alkyl-, -(O), -C₂₋₆-alkenyl-, -(O), -C₁₋₆-alkyl-O-, -(CH₂)_n-(C=O)-(CH₂)_m-, -O-

wherein

I is 0 or 1

k is 0 or 1

n and m are independently 0, 1, 2 or 3.

A is

Attorney Docket No. 6567.200-US
Sorensen et al.
Serial No. 10/735,963
Filed December 15, 2003

- o aryl, aryl-C₁₋₆-alkyl; heteroaryl, heteroaryl-C₁₋₆-alkyl, C₁₋₆-alkyl or C₃₋₈-cycloalkyl wherein the ring moieties optionally may be substituted with one or more substituents independently selected from R¹⁵
R¹⁵ is
 - halogen, nitro, cyano, hydroxy, C₁₋₆-alkylthio, C₁₋₆-alkylsulfonyl, C₁₋₆-alkylsulfonyloxy, C₁₋₆-alkyl, C₁₋₆-alkoxy, C₃₋₈-cycloalkyl, halo-C₁₋₆-alkyl, halo-C₁₋₆-alkoxy, -NR⁷R⁸, R⁷R⁸N-C₁₋₆-alkyl-, R⁷R⁸N-C₁₋₆-alkoxy-, or -O(C=O)NR⁷R⁸, or wherein two substituents in adjacent positions together form a radical -O-(CH₂)₁₋₃-O-, wherein R⁷ and R⁸ independently are hydrogen, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₁₋₆-alkanoyl or aryl, or R⁷ and R⁸ together with the nitrogen atom to which they are attached form a 3 to 7 membered, saturated or unsaturated ring, which may be fused to a benzene ring.
- o NR⁹R¹⁰ wherein R⁹ and R¹⁰ independently are hydrogen, C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₁₋₆-alkanoyl or aryl, or R⁹ and R¹⁰ together with the nitrogen atom to which they are attached form a 3 to 7 membered, saturated or unsaturated ring, which may be fused to a benzene ring, and the ring may contain further heteroatoms and it may optionally be substituted with one or more substituents independently selected from R¹⁶, wherein R¹⁶ is C₁₋₆-alkyl, C₃₋₈-cycloalkyl, C₁₋₆-alkanoyl or aryl optionally substituted with one or more substituents independently selected from R¹⁷, wherein R¹⁷ is halogen, nitro, cyano, hydroxy, or C₁₋₆-alkyl;

as well as any diastereomer or enantiomer or tautomeric form, mixtures of these, or a pharmaceutically acceptable salt thereof.

2. (Previously presented) A compound according to claim 1, wherein R¹ is C₃₋₈-cycloalkyl.

3. (Currently amended) A compound according to claim 2 ~~Error! Reference source not found.~~ wherein R¹ is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.

Attorney Docket No. 6567.200-US
Sorensen et al.
Serial No. 10/735,963
Filed December 15, 2003

4. (Currently Amended) A compound according to claim 3 ~~Error! Reference source not found.~~ wherein R¹ is cyclopropyl or cyclopentyl.

5. Cancelled

5. (Currently amended) A compound according to claim 4 ~~Error! Reference source not found.~~ wherein R¹ is cyclopropyl.

6. (Original) A compound according to claim 1, wherein X is a bond.

7. (Original) A compound according to claim 1, wherein s and t together are 0, 1, 2 or 3.

9. Cancelled

8. (Original) A compound according to claim 1 wherein s is 0 or 1.

9. (Original) A compound according to claim 10 wherein s is 0.

10. (Original) A compound according to claim 1 wherein t is 0.

13. Cancelled





14. Cancelled

15. Cancelled


16. Cancelled

17. Cancelled

18. (Previously presented) A compound according to claim 1, wherein Y is selected from



or



Attorney Docket No. 6567.200-US

Sorensen et al.

Serial No. 10/735,963

Filed December 15, 2003

19. (Original) A compound according to claim 1, wherein R⁴ is aryl, aryl-C₁₋₆-alkyl, either of which may optionally be substituted with one or more substituents independently selected from R¹⁴, or C₃₋₈-cycloalkyl optionally substituted with one or more substituents independently selected from R¹³.
20. (Original) A compound according to claim 19 wherein R⁴ is aryl optionally substituted with one or more substituents independently selected from R¹⁴.
21. (Original) A compound according to claim 19 wherein R⁴ is phenyl, biphenyl, or naphthyl optionally substituted with one or more substituents independently selected from R¹⁴.
22. (Original) A compound according to claim 21, wherein R⁴ is phenyl optionally substituted with one or more substituents independently selected from R¹⁴.
23. (Original) A compound according to claim 1 wherein R¹³ is C₁₋₆-alkyl.
24. (Original) A compound according to claim 1 wherein R¹⁴ is halogen, cyano, hydroxy, C₁₋₆-alkyl, C₁₋₆-alkylsulfonyl, C₁₋₆-alkylsulfonyloxy, C₁₋₆-alkoxy, C₃₋₈-cycloalkyl, -CF₃, -OCF₃, -NR⁵R⁶, R⁵R⁶N-C₁₋₆-alkyl-, or a group of the formula -(W)_k-A.
25. (Original) A compound according to claim 24 wherein R¹⁴ is F, Cl, cyano, methyl, ethyl, propyl, butyl, tert-butyl, methyl-sulfonyl, methylsulfonyloxy, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CF₃, -OCF₃, -NR⁵R⁶, R⁵R⁶N-methyl-, or a group of the formula -(W)_k-A.
26. (Original) A compound according to claim 25 wherein R¹⁴ is F, Cl, cyano, methyl, tert-butyl, methyl-sulfonyl, methoxy, cyclopentyl, cyclohexyl, -CF₃, -OCF₃, -NR⁵R⁶, R⁵R⁶N-methyl-, or a group of the formula -(W)_k-A.

Attorney Docket No. 6567.200-US
Sorenson et al.
Serial No. 10/735,963
Filed December 15, 2003

20 27. (Original) A compound according to claim 26 wherein R¹⁴ is a group of the formula
-(W)_k-A.

21 28. (Original) A compound according to claim 1, wherein k is 1.

22 29. (Original) A compound according to claim 1 wherein k is 0.

23 30. (Original) A compound according to claim 1 wherein W is -C₁₋₆-alkyl-,
-(O)-C₁₋₆-alkyl-O- -(CH₂)_n-(C=O)-(CH₂)_m-, or -O-.

24 31. (Original) A compound according to claim 30 wherein W is -C₁₋₆-alkyl- or -(CH₂)_n-
(C=O)-(CH₂)_m-.

25 32. (Original) A compound according to claim 31 wherein W is methylene, ethylene,
propylene or -(CH₂)_n-(C=O)-(CH₂)_m-.

26 33. (Original) A compound according to claim 1 wherein n is 0 or 1.

27 34. (Original) A compound according to claim 33 wherein n is 0.

28 35. (Previously presented) A compound according to claim 1 wherein m is 0 or 1.

29 36. (Original) A compound according to claim 35 wherein m is 0.

30 37. (Original) A compound according to claim 1 wherein l is 0.

31 38. (Original) A compound according to claim 1 wherein A is C₁₋₆-alkyl, aryl or
~~C₃₋₈-cycloalkyl~~, wherein the ring moieties optionally may be substituted with one or more
substituents independently selected from R¹⁵, or A is NR⁹R¹⁰.

Attorney Docket No. 6567.200-US
Sorensen et al.
Serial No. 10/735,963
Filed December 15, 2003

32 39. (Original) A compound according to claim 38 wherein A is methyl, ethyl, phenyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, wherein the ring moieties optionally may be substituted with one or more substituents independently selected from R¹⁵, or A is NR⁹R¹⁰.

33 40. (Original) A compound according to claim 39 wherein A is phenyl optionally substituted with one or more substituents independently selected from R¹⁵.

34 41. (Original) A compound according to claim 40 wherein A is phenyl.

35 42. (Original) A compound according to claim 39 wherein A is NR⁹R¹⁰.

36 43. (Original) A compound according to claim 1 wherein R¹⁵ is halogen, nitro, cyano, hydroxy, C₁₋₆-alkylthio, C₁₋₆-alkylsulfonyl, C₁₋₆-alkylsulfonyloxy, C₁₋₆-alkyl, C₁₋₆-alkoxy, C₃₋₈-cycloalkyl, halo-C₁₋₆-alkyl, or halo-C₁₋₆-alkoxy.


37 44. (Original) A compound according to claim 43 wherein R¹⁵ is halogen, cyano, hydroxy, CH₃-S-, CH₃CH₂-S-, methylsulfonyl, methylsulfonyloxy, methyl, ethyl, propyl, butyl, isopropyl, methoxy, ethoxy, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, -CF₃, or -OCF₃.

38 45. (Original) A compound according to claim 44 wherein R¹⁵ is halogen, methyl, ethyl, methoxy, ethoxy, -CF₃, or -OCF₃.

39 46. (Original) A compound according to claim 1 wherein R⁹ and R¹⁰ together with the nitrogen atom to which they are attached form a 3 to 7 membered, saturated or unsaturated ring, which may be fused to a benzene ring, and the ring may contain further heteroatoms and it may optionally be substituted with one or more substituents independently selected from R¹⁶.

40 47. (Original) A compound according to claim 46 wherein R⁹ and R¹⁰ together with the nitrogen atom to which they are attached form a structure selected from

Attorney Docket No. 6567.200-US
Sorensen et al.
Serial No. 10/735,963
Filed December 15, 2003



48. (Original) A compound according to claim 1 wherein R¹⁶ is methyl, ethyl, 1-ethyl-propyl or phenyl optionally substituted with one or more substituents independently selected from R¹⁷.

49. (Original) A compound according to claim 1 wherein R¹⁷ is halogen.

50. (Original) A pharmaceutical composition comprising, as an active ingredient, at least one compound according to claim 1 together with one or more pharmaceutically acceptable carriers or excipients.

51. (Currently amended) A pharmaceutical composition according to claim 50 in unit dosage form, comprising from about 0.05 mg to about 1000 mg, preferably from about 0.1 mg to about 500 mg or and especially preferred from about 0.5 mg to about 200 mg of the compound.

52. (Original) A pharmaceutical composition according to claim 50 wherein the compound exhibits histamine H3 antagonistic activity or histamine H3 inverse agonistic activity.

53. Cancelled

54. Cancelled

55. Cancelled

56. Cancelled

57. Cancelled

58. Cancelled

59. Cancelled

60. Cancelled

61. Cancelled

Attorney Docket No. 6567.200-US
Sorensen et al.
Serial No. 10/735,963
Filed December 15, 2003

62. Cancelled

63. Cancelled

64. Cancelled

65. Cancelled

66. Cancelled

67. Cancelled